Related Experiment Video

Updated: Feb 14, 2026

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

991

Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy

Gamariel Rwibasira Rudinga1, Ghulam Jilany Khan2, Yi Kong3

  • 1School of Life Science & Technology, China Pharmaceutical University, 24 Tong Jia Street, Nanjing 210009, China. 2720150013@stu.cpu.edu.cn.

International Journal of Molecular Sciences
|February 15, 2018
PubMed

Insights

Targeting protease-activated receptor 4 (PAR4) offers a safer strategy for preventing thrombosis and cardiovascular diseases (CVDs). PAR4 antagonists show potential for improved cardiac protection and managing inflammatory responses.

Area of Science:

  • Molecular Biology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cardiovascular diseases (CVDs) are a leading global cause of mortality.
  • Platelet aggregation, a key factor in arterial thrombi, significantly contributes to CVDs.
  • Protease-activated receptors (PARs), specifically PAR1 and PAR4 expressed on human platelets, are implicated in platelet activation and inflammatory signaling relevant to CVDs.

Purpose of the Study:

  • To review the structural characteristics and activation mechanisms of PAR4.
  • To elucidate the role of PAR4 in the pathophysiology of cardiovascular diseases.
  • To explore the potential of PAR4 targeting as a strategy for improved cardiac protection and thrombosis prevention.

Main Methods:

  • Literature review summarizing existing research on PAR4.
  • Analysis of PAR4's structural features and activation pathways.
  • Evaluation of PAR4's involvement in platelet function and inflammatory processes.

Main Results:

  • PAR4 plays a critical role in platelet activation and modulates inflammatory responses.
  • Current antiplatelet drugs have limitations due to side effects.
  • Targeting PAR4 presents a potentially safer therapeutic strategy for thrombosis prevention.

Conclusions:

  • PAR4 antagonists are highlighted for their potential utility in managing various cardiovascular diseases.
  • PAR4 targeting represents a promising avenue for enhancing cardiac safety and reducing thrombotic events.
  • Further research into PAR4 antagonists could lead to improved treatments for CVDs.

Keywords:
PAR4 antagonistplateletprotease-activated receptor 4 (PAR4)thrombinthrombosis

More Related Videos

Use of the Protease Fluorescent Detection Kit to Determine Protease Activity09:00

Use of the Protease Fluorescent Detection Kit to Determine Protease Activity

Published on: August 4, 2009

28.9K
Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE12:43

Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE

Published on: July 29, 2014

12.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.8K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.8K
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
111.6K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K
G-protein Coupled Receptors01:21

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
132.2K